Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors
Andrea Wang‐Gillam, Richard Hubner, Jens T. Siveke, et al.
European Journal of Cancer (2019) Vol. 108, pp. 78-87
Open Access | Times Cited: 249

Showing 1-25 of 249 citing articles:

DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy
Ruixue Huang, Ping‐Kun Zhou
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 515
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Bruno Bockorny, Valerya Semenisty, Teresa Macarulla, et al.
Nature Medicine (2020) Vol. 26, Iss. 6, pp. 878-885
Closed Access | Times Cited: 409
Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment
Wenxi Zhou, Yu Zhou, Xinli Chen, et al.
Biomaterials (2020) Vol. 268, pp. 120546-120546
Closed Access | Times Cited: 344
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
John H. Strickler, Hironaga Satake, Thomas J. George, et al.
New England Journal of Medicine (2022) Vol. 388, Iss. 1, pp. 33-43
Open Access | Times Cited: 274
Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
Mateusz Kciuk, Beata Marciniak, Renata Kontek
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 14, pp. 4919-4919
Open Access | Times Cited: 185
Advances in phytochemical delivery systems for improved anticancer activity
Ricardo Lagoa, João Silva, Joaquim Rui Rodrigues, et al.
Biotechnology Advances (2019) Vol. 38, pp. 107382-107382
Closed Access | Times Cited: 180
Translational advances in pancreatic ductal adenocarcinoma therapy
Abdel Hosein, Stephanie K. Dougan, Andrew J. Aguirre, et al.
Nature Cancer (2022) Vol. 3, Iss. 3, pp. 272-286
Open Access | Times Cited: 177
The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy
Daniel R. Principe, Patrick W. Underwood, Murray Korc, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 157
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation
Tanios Bekaii‐Saab, Rona Yaeger, Alexander I. Spira, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 25, pp. 4097-4106
Open Access | Times Cited: 151
Treatment landscape of metastatic pancreatic cancer
Sara De Dosso, Alexander Siebenhüner, Thomas Winder, et al.
Cancer Treatment Reviews (2021) Vol. 96, pp. 102180-102180
Closed Access | Times Cited: 138
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial
Kim A. Reiss, Rosemarie Mick, Ursina Teitelbaum, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 8, pp. 1009-1020
Open Access | Times Cited: 80
Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery
Fatemeh Davodabadi, Seyedeh Fatemeh Sajjadi, Mohammad Sarhadi, et al.
European Journal of Pharmacology (2023) Vol. 958, pp. 176013-176013
Closed Access | Times Cited: 57
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 41
Advances and applications of nanoparticles in cancer therapy
Xianzhou Huang, Tao He, Xiuqi Liang, et al.
MedComm – Oncology (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 26
Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept
Wenyu Luo, Ti Wen, Xiujuan Qu
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 24
Targeting KRAS in pancreatic cancer
Sandra Stickler, Barbara H. Rath, Gerhard Hamilton
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 5, pp. 799-805
Open Access | Times Cited: 18
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial
Arndt Vogel, Anna Saborowski, Patrick Wenzel, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 8, pp. 734-744
Open Access | Times Cited: 17
Wnt/β-Catenin Signaling: The Culprit in Pancreatic Carcinogenesis and Therapeutic Resistance
Monish Ram Makena, Himavanth R. Gatla, Dattesh Verlekar, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 17, pp. 4242-4242
Open Access | Times Cited: 136
Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy
Ayeskanta Mohanty, Saji Uthaman, In‐Kyu Park
Molecules (2020) Vol. 25, Iss. 19, pp. 4377-4377
Open Access | Times Cited: 111
Overcoming Physiological Barriers to Nanoparticle Delivery—Are We There Yet?
Oliver S. Thomas, Wilfried Weber
Frontiers in Bioengineering and Biotechnology (2019) Vol. 7
Open Access | Times Cited: 106
ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer
Silvia Catanese, George Pentheroudakis, Jean-Yves Douillard, et al.
ESMO Open (2020) Vol. 5, pp. e000804-e000804
Open Access | Times Cited: 85
Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants
Milind Javle, Einat Shacham‐Shmueli, Lianchun Xiao, et al.
JAMA Oncology (2021) Vol. 7, Iss. 5, pp. 693-693
Open Access | Times Cited: 84
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
James E. Frampton
Drugs (2020) Vol. 80, Iss. 10, pp. 1007-1018
Open Access | Times Cited: 76
Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Bruno Bockorny, Teresa Macarulla, Valerya Semenisty, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 18, pp. 5020-5027
Open Access | Times Cited: 63
Nanotechnology-Based Strategies to Overcome Current Barriers in Gene Delivery
Sofía Mirón‐Barroso, Elena B. Domènech, Sònia Trigueros
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8537-8537
Open Access | Times Cited: 60
Page 1 - Next Page

Scroll to top